Accordingly, BRAF inhibitors vemurafenib, dabrafenib, and encorafenib, as well as mitogen-activated protein kinase kinase (MEK) inhibitor trametinib, cobimetinib, and binimetinib, are applied to the targeted treatment of melanoma (5, 6). Here, BRAF is linked to melanoma.